Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SZShujuan ZhouShanghai Medical College of Fudan UniversityYSYifen ShiWenzhou Medical UniversitySJSongfu JiangWenzhou Medical University

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates complete response in marginal zone lymphoma with orelabrutinib and obinutuzumab, suggesting manageable adverse events.

Key Points

  • To evaluate the efficacy and safety of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma.
  • Prospective, single-arm, phase II clinical trial
  • Patients with untreated MZL received orelabrutinib and obinutuzumab
  • Primary endpoint: overall response rate; secondary endpoints: CR rate, PFS, and OS
  • 100% overall response rate in evaluable patients
  • 88% complete response achieved
  • 12-month progression-free survival and overall survival both 100%

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d71fhttps://doi.org/10.1182/blood-2025-7121
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  2. 2Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  3. 3Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  4. 4Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  5. 5Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations